sorafenib has been researched along with Pulmonary Hypertension in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, K; Inami, T; Kataoka, M; Kimura, G; Satoh, T; Yoshino, H | 1 |
| Guignabert, C; Humbert, M; Montani, D; Weatherald, J | 1 |
| Hikasa, Y; Leong, ZP | 1 |
| Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y | 1 |
| Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N | 1 |
| Archer, SL; Barst, RJ; Bond, L; Coslet, S; Gomberg-Maitland, M; Lacouture, ME; Maitland, ML; Perrino, TJ; Ratain, MJ; Sugeng, L | 1 |
| Garcia, JG; Moreno-Vinasco, L | 1 |
| Abe, K; Alzoubi, A; Fagan, KA; Gairhe, S; Gerthoffer, WT; Ito, M; Koubsky, K; McMurtry, IF; Oka, M; Ota, H; Toba, M | 1 |
| Baumann, C; Dahal, BK; Davie, N; Evans, S; Fairman, D; Ghofrani, HA; Grimminger, F; Kilty, I; Kojonazarov, B; Kosanovic, D; Luitel, H; Majewski, M; Phillips, P; Pullamsetti, SS; Schermuly, RT; Seeger, W; Sydykov, A; Tian, X; Wayman, C; Weissmann, N | 1 |
| Fukuda, K; Kataoka, M; Ono, T; Sano, M; Satoh, T; Tamura, Y | 1 |
| Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA | 1 |
2 review(s) available for sorafenib and Pulmonary Hypertension
| Article | Year |
|---|---|
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension.
Topics: Animals; Benzenesulfonates; Calmodulin-Binding Proteins; Gene Expression; Gene Expression Profiling; Hemodynamics; Humans; Hypertension, Pulmonary; Lung; Microarray Analysis; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib | 2010 |
1 trial(s) available for sorafenib and Pulmonary Hypertension
| Article | Year |
|---|---|
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Benzenesulfonates; Diarrhea; Drug Discovery; Drug Dosage Calculations; Exanthema; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
8 other study(ies) available for sorafenib and Pulmonary Hypertension
| Article | Year |
|---|---|
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension.
Topics: Adolescent; Adult; Arterial Pressure; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Female; Heart Failure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Treatment Outcome | 2017 |
Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension".
Topics: Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Indoles; Male; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pulmonary Artery; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2018 |
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Topics: Animals; Benzamides; Benzenesulfonates; Blood Pressure; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Heart; Heart Ventricles; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyridines; Pyrimidines; raf Kinases; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Ventricular Remodeling | 2008 |
Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Topics: Animals; Antihypertensive Agents; Benzamides; Benzenesulfonates; Blotting, Western; Calcium; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Imatinib Mesylate; Male; Myosin Light Chains; Myosin-Light-Chain Phosphatase; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Artery; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Sorafenib; Vasodilation; Vasodilator Agents; Ventricular Function, Left; Ventricular Function, Right; Ventricular Pressure | 2011 |
Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
Topics: Animals; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Ventricular Function, Right; Ventricular Remodeling | 2013 |
Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension.
Topics: Adult; Benzenesulfonates; Cardiac Catheterization; Exercise Test; Female; Humans; Hypertension, Pulmonary; Neurofibromatosis 1; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vascular Resistance | 2012 |
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Complement C1q; Disease Models, Animal; Enzyme Activation; Gene Expression Profiling; Genomics; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Mitogen-Activated Protein Kinases; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred Dahl; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transforming Growth Factor beta3; Vascular Endothelial Growth Factor Receptor-2 | 2008 |